Dexcom's Stelo CGM Wins Key FDA Pediatric Clearance

The FDA has expanded the clearance for Dexcom's over-the-counter Stelo continuous glucose monitor (CGM). Previously authorized only for adults 18 and older, Stelo is now the first OTC CGM cleared for use by children aged 2 and up who do not use insulin. This decision allows the device to be marketed to a much larger population.

The clearance comes at a time when prediabetes is affecting a growing number of children in the U.S., increasing their long-term risk of developing Type 2 diabetes. The FDA's move effectively creates a new, preventative-use category for CGMs beyond traditional diabetes management.

The Stelo system works via a wearable sensor that pairs with a smartphone. It tracks glucose levels automatically every 15 minutes, providing continuous data and trends. Each sensor is designed to last up to 15 days, though the FDA notes wear time may be shorter for kids due to behavioral and physiological differences.

Notably, the FDA based its decision in part on real-world evidence. Dexcom and the agency evaluated data from past clinical studies and real-world usage from current CGM users to assess the device's expected performance over the full wear period.

This regulatory milestone is a direct growth catalyst for Dexcom. By entering the pediatric and adolescent market, the company significantly expands its total addressable market (TAM). It moves Stelo from a tool for adult wellness into the realm of family health and early intervention for at-risk youth.

Financially, this opens a substantial new revenue stream. The OTC model means parents can purchase Stelo without a prescription, simplifying access and potentially driving higher sales volume. It positions Dexcom ahead of competitors in the non-insulin using CGM segment, especially for younger users.

Strategically, getting children and families accustomed to Dexcom's ecosystem creates powerful brand loyalty. Users who start with Stelo for prediabetes management may naturally transition to Dexcom's prescription products like the G7 if they later develop diabetes requiring insulin, creating a long-term customer pipeline.

While the stock's immediate reaction was muted, likely tied to broader market conditions, the long-term implications are positive. It demonstrates regulatory agility and strengthens Dexcom's narrative as an innovator in proactive health management, not just reactive disease treatment.